TB-402 is a human antibody binding to Factor VIII, which plays a crucial role in the coagulation of the blood. It is expected to be developed as a potential treatment to prevent blood clot formation in connection with certain types of heart arrhythmia, such as atrial fibrillation.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of TB-402. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of TB-402. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of TB-402. |
| Estrone | Estrone may increase the thrombogenic activities of TB-402. |
| Estradiol | Estradiol may increase the thrombogenic activities of TB-402. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of TB-402. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of TB-402. |
| Mestranol | Mestranol may increase the thrombogenic activities of TB-402. |
| Estriol | Estriol may increase the thrombogenic activities of TB-402. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of TB-402. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of TB-402. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of TB-402. |
| Tibolone | Tibolone may increase the thrombogenic activities of TB-402. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of TB-402. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of TB-402. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of TB-402. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of TB-402. |
| Zeranol | Zeranol may increase the thrombogenic activities of TB-402. |
| Equol | Equol may increase the thrombogenic activities of TB-402. |
| Promestriene | Promestriene may increase the thrombogenic activities of TB-402. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of TB-402. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of TB-402. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of TB-402. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of TB-402. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of TB-402. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of TB-402. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of TB-402. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of TB-402. |
| Formononetin | Formononetin may increase the thrombogenic activities of TB-402. |
| Estetrol | Estetrol may increase the thrombogenic activities of TB-402. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with TB-402. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with TB-402. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with TB-402. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with TB-402. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with TB-402. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with TB-402. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with TB-402. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with TB-402. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with TB-402. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with TB-402. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with TB-402. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with TB-402. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with TB-402. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with TB-402. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with TB-402. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with TB-402. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with TB-402. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with TB-402. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with TB-402. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with TB-402. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with TB-402. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with TB-402. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with TB-402. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with TB-402. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with TB-402. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with TB-402. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with TB-402. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with TB-402. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with TB-402. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with TB-402. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with TB-402. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with TB-402. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with TB-402. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with TB-402. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with TB-402. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with TB-402. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with TB-402. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with TB-402. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with TB-402. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with TB-402. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with TB-402. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with TB-402. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with TB-402. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with TB-402. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with TB-402. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with TB-402. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with TB-402. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with TB-402. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with TB-402. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with TB-402. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with TB-402. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with TB-402. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with TB-402. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with TB-402. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with TB-402. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with TB-402. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with TB-402. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with TB-402. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with TB-402. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with TB-402. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with TB-402. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with TB-402. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with TB-402. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with TB-402. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with TB-402. |
| Caplacizumab | The risk or severity of adverse effects can be increased when TB-402 is combined with Caplacizumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when TB-402 is combined with IMC-1C11. |
| Eldelumab | The risk or severity of adverse effects can be increased when TB-402 is combined with Eldelumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when TB-402 is combined with Lumiliximab. |
| Canakinumab | The risk or severity of adverse effects can be increased when TB-402 is combined with Canakinumab. |